Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03634501
Other study ID # XuanWuH-NK
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 26, 2018
Est. completion date September 30, 2022

Study information

Verified date January 2019
Source Xuanwu Hospital, Beijing
Contact Zhiguo Chen, PhD
Phone 86-10-83198889
Email chenzhiguo@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will analyze and evaluate the following items:

1. The safety of natural killer(NK) cells for treatment of subjects with solid tumors. Forty patients will be enrolled for each of the five cancers (in total 200 patients will be enrolled).

2. The effectiveness of natural killer(NK)cell therapy alone or with chemotherapy or targeted drugs.

Subjects from 18 to 75 years of age who are diagnosed with a solid tumor including pancreatic cancer, lung cancer, breast cancer, ovarian cancer and colon cancer, and for whom standard treatments are not effective, may be eligible for this study. Participants undergo the following procedures:

Peripheral blood will be collected from a vein of arm. Peripheral blood mononuclear cells(PBMC) will be isolated and purified for NK manufacturing. After 14~21 days cultivation, activated NK will be harvested and formulated for clinical administration.

Subjects will receive NK cell treatment by intravenous infusion. The frequency is once every 3 or 4 weeks for the first 3 months. Participants who respond well after 3 months may be eligible to continue NK cell therapy; and those not may receive NK therapy combined with chemotherapy and/or targeted drugs, or chemotherapy/targeted drugs alone.

Evaluations during therapy including:

1. Clinical assessment, and history of medications;

2. Blood draws for routine and research tests, including but not limited to: lymphocyte population and circulating tumor cell analysis in peripheral blood;

3. CT scan, bone scan and positron emission tomography(PET )scan, if indicated, for disease evaluation;

4. Pharmacokinetics study after NK infusion. For this test, the number of NK cells in the blood is measured over time at indicated time-points.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date September 30, 2022
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age from 18 to 75 years (including boundary values);

2. Diagnosed with histologically and cellularly confirmed cancer of lung, breast, pancreas, ovary, or colon;

3. At least 8 weeks since any prior systemic therapy to treat the underlying malignancy (standard or investigational);

4. Life expectancy > 6 months, and performance status(KPS)> 60 points;

5. Organ functions meet the following criteria:

1. Blood bilirubin < 2mg/dL,

2. Aspartate transaminase(AST)<100 IU/L,

3. Alanine transaminase(ALT) <100 IU/L,

4. Creatinine <1.5 mg/dL,

5. Urea nitrogen = 25 mg/dL,

6. Hemoglobin = 9.0 g/dL,

7. White blood cell count>3.5×109/L,

8. Neutrophil count >1.5x109/L,

9. Platelet count > 80 × 109 /L,

10. Hematocrit >0.20,

6. No severe infections.

Exclusion Criteria:

1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except inhaled steroids);

2. Patients who take chemotherapy within 1 month prior to treatment;

3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic cells within two weeks prior to treatment;

4. Patients with T lymphoma and NK cell lymphoma;

5. Patients with autoimmune diseases, including but not limited to lupus erythematosus, rheumatoid arthritis, etc.;

6. Seriously uncontrollable infected patients;

7. Patients who are allergic to the biological agents in this treatment;

8. Patients with organ transplantation or organ failure;

9. Subjects with severe cardiovascular disease and severe renal failure;

10. Patients who are undergoing treatment of immunosuppressive drugs or long-term administration of immunosuppressive drugs after organ transplantation;

11. Patients with active infection or fever;

12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal dysfunction;

13. Subjects with pregnancy or during the lactating period.

Study Design


Intervention

Biological:
Activated NK
Cell suspension

Locations

Country Name City State
China Xuanwu Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of toxicity induced by NK infusion The incidence of toxicity within each infusion within 6 months after NK administration 6 months
Secondary Objective-response rate (ORR) Objective-response rate (ORR): defined as the proportion of patients who achieve partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at any time on study. 6 months after 6 infusions of NK administration
Secondary Persistence of NK Duration of NK persistence: defined as duration from Day 1 to the time when the NK level goes back to stable level Day 0, Day 7, Day30, Day 60, Day 90, Day 180
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Enrolling by invitation NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT04190381 - A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy N/A
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT02894398 - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Phase 2
Completed NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Phase 1